Browsing ICR Divisions by author "Feber, Andrew"
Now showing items 1-4 of 4
-
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual, J; Gil-Gil, M; Proszek, P; Zielinski, C; Reay, A; et al. (AMER ASSOC CANCER RESEARCH, 2023-10-13)PURPOSE: Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early ... -
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Mostafid, AH; Porta, N; Cresswell, J; Griffiths, TRL; Kelly, JD; et al. (WILEY, 2020-06-01)OBJECTIVES: To evaluate the activity of intravesical mitomycin-C (MMC) to ablate recurrent low-risk non-muscle-invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for ... -
Pan-cancer deconvolution of tumour composition using DNA methylation.
Chakravarthy, A; Furness, A; Joshi, K; Ghorani, E; Ford, K; et al. (NATURE PUBLISHING GROUP, 2018-08-13)The nature and extent of immune cell infiltration into solid tumours are key determinants of therapeutic response. Here, using a DNA methylation-based approach to tumour cell fraction deconvolution, we report the integrated ... -
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
Wong, YNS; Joshi, K; Khetrapal, P; Ismail, M; Reading, JL; et al. (ROCKEFELLER UNIV PRESS, 2018-11-05)Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to checkpoint blockade, highlighting a need to better understand drug resistance and identify rational ...